UN ACCOMPAGNEMENT « Au sein de Nemera, notre offre ne se FULL GUIDANCE THAT COMPLET CHEZ NEMERA, focalise pas uniquement sur le dispositif COMES WITH SPEED AND GAGE DE RAPIDITÉ ET d’injection, nous cherchons à proposer COST-SAVINGS AT NEMERA D’ÉCONOMIE une offre complète pour nos clients, note Séverine Duband, Global Category “At Nemera, our offering does not Director chez Nemera. C’est pourquoi exclusively focus on the injection device, notre objectif est vraiment de maîtriser but we are also seeking to come with a l’ensemble des composants de la chaîne full offering for our customers, Sévérine de valeur du produit, au-delà de l’aspect Duband, Global Category Director at « mécanique » du dispositif. Cette Nemera says. Therefore the objective stratégie passe par de l’intégration, comme is to really master the whole set of c’est le cas avec nos filiales « Insight components, from the value chain of the Innovation Center » à Chicago, aux product well beyond the “mechanic” Etats-Unis, qui sont spécialisées dans la aspect of the device. This strategy goes réalisation d’études patients et de services through integration, as is the case with our associés. Mais elle s’illustre aussi au “Insight Innovation Centre” subsidiaries travers de partenariats clés. Un exemple in Chicago, USA, which are specialized in avec notre dispositif Safe’n’Sound pour® carrying out clinical studies on patients lequel nous travaillons aussi bien avec and the related services. But this is also les fabricants de seringues pré-remplies, visible through our key partnerships. qu’avec les fournisseurs de machines Such an example is our Safe’n’Sound® d’assemblages, pour proposer une solution device on which we are working both pré-validée à nos clients, ce qui leur with the manufacturers of prefilled La gamme de produits Safe’n’Sound® permet d’aller plus vite et à moindre coût syringes, assembly machine suppliers in de Nemera comprend des dispositifs order to present a pre-validated solution sur le marché. Nous sommes également to our clients so that they can launch de sécurité passifs pour seringues en capacité de proposer des services their products faster and at a lower cost. préremplies qui visent à sécuriser associés au développement du médicament We are also able to offer services related l’injection pour les professionnels de santé final, tels que des études patients, des to the development of the final drug, et l’auto-administration pour les patients. tests laboratoires, des dispositifs dédiés such as studies on patients, laboratory à la formation de nos clients ou de nos tests, devices dedicated to training our Nemera’s range of Safe’n’Sound products® patients…. Un accompagnement donc clients or patients... A complex and fully includes passive security devices for complet et intégré, de la recherche et integrated support, from research and prefilled syringes designed to secure l’ingénierie en conception, en intégrant les design engineering while integrating human injection administration by health facteurs humains, jusqu’aux capacités de factors and up to clinical and commercial professionals and self-administration by fabrication cliniques et commerciales, et manufacturing capabilities and monitoring patients. au suivi après lancement sur le marché. » after the launch on the market.” be tested as part of usage trials,” he says. also improves the value proposals of says. In addition, there is also an increase In fact, this year EVEON reached a new both partners on the promising market in targeted therapies dedicated to speci- milestone in its development by offering for digital therapies. fic patients, which require an increased digital therapy with BePatient. This personalization of health as a whole. solution allows connecting the devices Future prospects And efforts are still to be made in terms to their platform in order to ensure com- of environmental impact, an area where munication between patients and health As we can see, the injectable market is there is still lots to be done on injection professionals. “The applications target constantly evolving. The trends emerging systems. “This starts from the research securing treatment administration during over the past years should continue and of more sustainable materials, from the clinical trials but also when the medical they will most surely be closely monitored choice of using reusable systems when devices are used in real life settings by in order to adapt portfolios to market these latter embed electronic components allowing treatment adherence tracking needs. “At Nemera, we focus on bringing in order to limit waste and goes up to the and remote monitoring,” he explains. connectivity and digitization in the health product life cycle analysis,” she concludes. Beyond improving the care pathway and sector, on the concept of ‘services linked’ patient involvement with the aid of IoTs to a product and the growing demand for Article written by and data intelligence, this partnership a ‘turnkey’ solution,” Séverine Duband Marion Baschet-Vernet October - 2021 / The Pharmaceutical Post 08 29 KCAP